Download Airfinity's COVID-19 Vaccine Expiry Forecast for 2021 and 2022
Therapy Areas
Solutions for
Contact us

Airfinity forecasts fewer doses to be delivered this year than COVAX

Posted on Jul 21, 2021
Airfinity background image landing page

Airfinity is forecasting a 24.3% shortfall in deliveries to COVAX this year than is forecasted by the scheme.

COVAX is forecasting 1.86b vaccine doses to be delivered by the end of December 2021. Based on analysis of doses secured to date, Airfinity is forecasting this to be 1.407b doses delivered.

Airfinity’s number is lower due to several factors that are considered, rather than taking company projections at face-value, which have often not been realised. COVAX are expecting deliveries from vaccines that are yet to be approved and in some cases efficacy data is not yet available, such as Clover and Sanofi/GSK.

Airfinity’s forecasts also use real-time production data and historic trends in scale-up challenges, resulting in a lower output than COVAX have forecast, notably in candidates such as Novavax, who have shown many difficulties in their fragmented production network.

For more information or if you have specific data requests, contact the team at

Document Library

Sign up to receive a free sample of our insights

Airfinity will never share your data with any third parties. By completing this form you are agreeing to being contacted for marketing and product communications. Our Privacy Policy can be found here.

For verified organisations only.

To schedule a demo today, contact us. To receive our media briefings, email


Sign up to receive the latest insights, product updates and news from Airfinity.

Copyright © Airfinity Limited 2021.
Privacy Policy